Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: Impact on biomarker testing

Translational Lung Cancer Research

Volumn 5, Issue 6, 2016, Pages 665-672

  Pérez Barrios, Clara ^a   Nieto Alcolado, Irene ^a   Torrente, María ^a   Jiménez Sánchez, Carolina ^a   Calvo, Virginia ^a   Gutierrez Sanz, Lourdes ^a   Palka, Magda ^a   Donoso Navarro, Encarnación ^a   Provencio, Mariano ^a   Romero, Atocha ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cancer; Circulating free DNA (cfDNA); Epidermal growth factor receptor (EGFR); KRAS

Indexed keywords

CIRCULATING FREE DNA; DNA; DNA FRAGMENT; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLOOD; BLOOD ANALYSIS EQUIPMENT; CANCER PATIENT; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DNA ISOLATION; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; LUNG CANCER; MAGNA PURE COMPACT NUCLEIC ACID ISOLATION KIT I; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; QIAAMP CIRCULATING NUCLEID ACID KIT; RSC CCFDNA PLASMA KIT; TUMOR LOCALIZATION;

EID: 85010190079     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.21037/tlcr.2016.12.03     Document Type: Article

References (23)

1. International Agency for Research on Cancer, Cutado MP, Edwards B, et al. Cancer Incidence in Five Continents: Volume IX. Lyon: International Agency for Research on Cancer, 2008.
2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
3. American Society of Clinical Oncology. The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract 2014;10:119-42.
4. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007;581:795-9.
5. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
6. Aung KL, Board RE, Ellison G, et al. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J 2010;4:11-21.
7. Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472-84.
8. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
9. He C, Liu M, Zhou C, et al. Detection of epidermal growth factor receptor mutations in plasma by mutantenriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009;125:2393-9.
10. Kuang Y, Rogers A, Yeap BY, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant nonsmall cell lung cancer. Clin Cancer Res 2009;15:2630-6.
11. Romero A, Acosta-Eyzaguirre D, Sanz J, et al. Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulatingfree DNA a powerful tool for biomarker testing in advance disease. Transl Res 2015;166:783-7.
12. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
13. Suzuki N, Kamataki A, Yamaki J, et al. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta 2008;387:55-8.
14. Repiská G, Sedlácková T, Szemes T, et al. Selection of the optimal manual method of cell free fetal DNA isolation from maternal plasma. Clin Chem Lab Med 2013;51:1185-9.
15. Fong SL, Zhang JT, Lim CK, et al. Comparison of 7 methods for extracting cell-free DNA from serum samples of colorectal cancer patients. Clin Chem 2009;55:587-9.
16. Holmberg RC, Gindlesperger A, Stokes T, et al. Akonni TruTip(®) and Qiagen(®) methods for extraction of fetal circulating DNA-evaluation by real-time and digital PCR. PLoS One 2013;8:e73068.
17. Kuhlmann JD, Schwarzenbach H, Wimberger P, et al. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer 2012;12:325.
18. Schwarzenbach H, Eichelser C, Kropidlowski J, et al. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res 2012;18:5719-30.
19. Holdenrieder S, Stieber P, Förg T, et al. Apoptosis in serum of patients with solid tumours. Anticancer Res 1999;19:2721-4.
20. Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 2001;95:114-20.
21. Holdenrieder S, Stieber P, Bodenmüller H, et al. Circulating nucleosomes in serum. Ann N Y Acad Sci 2001;945:93-102.
22. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669-79; discussion 1680.
23. Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009;106:19503-8.